{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T03:50:42Z","timestamp":1782791442234,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40257-020-00513-3","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T10:05:53Z","timestamp":1584353153000},"page":"557-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1612-3887","authenticated-orcid":false,"given":"Payal M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9851-260X","authenticated-orcid":false,"given":"Virginia A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn N.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-2454","authenticated-orcid":false,"given":"Kyle T.","family":"Amber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,16]]},"reference":[{"issue":"1","key":"513_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","volume":"54","author":"KT Amber","year":"2018","unstructured":"Amber KT, Murrell DF, Schmidt E, Joly P, Borradori L. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management. Clin Rev Allergy Immunol. 2018;54(1):26\u201351. https:\/\/doi.org\/10.1007\/s12016-017-8633-4.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9863","key":"513_CR2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320\u201332. https:\/\/doi.org\/10.1016\/S0140-6736(12)61140-4.","journal-title":"Lancet"},{"key":"513_CR3","doi-asserted-by":"publisher","first-page":"j2169","DOI":"10.1136\/bmj.j2169","volume":"357","author":"M Kayani","year":"2017","unstructured":"Kayani M, Aslam AM. Bullous pemphigoid and pemphigus vulgaris. BMJ. 2017;357:j2169. https:\/\/doi.org\/10.1136\/bmj.j2169.","journal-title":"BMJ"},{"issue":"5","key":"513_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321\u20137. https:\/\/doi.org\/10.1056\/NEJMoa011592.","journal-title":"N Engl J Med"},{"issue":"7","key":"513_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","volume":"129","author":"P Joly","year":"2009","unstructured":"Joly P, Roujeau JC, Benichou J, Delaporte E, D\u2019Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Investig Dermatol. 2009;129(7):1681\u20137. https:\/\/doi.org\/10.1038\/jid.2008.412.","journal-title":"J Investig Dermatol."},{"issue":"4","key":"513_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, Zambruno G, Zillikens D, Ioannides D, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172(4):867\u201377. https:\/\/doi.org\/10.1111\/bjd.13717.","journal-title":"Br J Dermatol"},{"issue":"8","key":"513_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/ddg.12606","volume":"13","author":"R Eming","year":"2015","unstructured":"Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H, et al. S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13(8):833\u201344. https:\/\/doi.org\/10.1111\/ddg.12606.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"5","key":"513_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jaad.2017.10.035","volume":"78","author":"A Lamberts","year":"2018","unstructured":"Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol. 2018;78(5):989\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2017.10.035(e2).","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"513_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.23736\/S0392-0488.18.06006-6","volume":"153","author":"E Cozzani","year":"2018","unstructured":"Cozzani E, Marzano AV, Caproni M, Feliciani C, Calzavara-Pinton P, Cutaneous Immunology group of SIDeMaST. Bullous pemphigoid: Italian guidelines adapted from the EDF\/EADV guidelines. G Ital Dermatol Venereol. 2018;153(3):305\u201315. https:\/\/doi.org\/10.23736\/S0392-0488.18.06006-6.","journal-title":"G Ital Dermatol Venereol"},{"key":"513_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15111","author":"H Ujiie","year":"2019","unstructured":"Ujiie H, Iwata H, Yamagami J, Nakama T, Aoyama Y, Ikeda S, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol. 2019. https:\/\/doi.org\/10.1111\/1346-8138.15111.","journal-title":"J Dermatol"},{"issue":"3","key":"513_CR11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","volume":"66","author":"DF Murrell","year":"2012","unstructured":"Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2011.06.032.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"513_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.annder.2011.01.009","volume":"138","author":"P Bernard","year":"2011","unstructured":"Bernard P, Bedane C, Prost C, Ingen-Housz-Oro S, Joly P, Centres de reference des maladies bulleuses auto-immunes. Societe Francaise de D. Bullous pemphigoid. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie [in French]. Ann Dermatol Venereol. 2011;138(3):247\u201351. https:\/\/doi.org\/10.1016\/j.annder.2011.01.009.","journal-title":"Ann Dermatol Venereol."},{"issue":"6","key":"513_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","volume":"167","author":"VA Venning","year":"2012","unstructured":"Venning VA, Taghipour K, Mohd Mustapa MF, Highet AS, Kirtschig G. British Association of Dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012. Br J Dermatol. 2012;167(6):1200\u201314. https:\/\/doi.org\/10.1111\/bjd.12072.","journal-title":"Br J Dermatol"},{"issue":"2 Suppl 1","key":"513_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1590\/abd1806-4841.2019940207","volume":"94","author":"CG Santi","year":"2019","unstructured":"Santi CG, Gripp AC, Roselino AM, Mello DS, Gordilho JO, Marsillac PF, et al. Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita\u2014Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl 1):33\u201347. https:\/\/doi.org\/10.1590\/abd1806-4841.2019940207.","journal-title":"An Bras Dermatol."},{"issue":"3","key":"513_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.annder.2011.01.015","volume":"138","author":"S Ingen-Housz-Oro","year":"2011","unstructured":"Ingen-Housz-Oro S, Bedane C, Prost C, Joly P, Bernard P, Centres de r\u00e9f\u00e9rence des maladies bulleuses auto-immunes, Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie. Pemphigoid gestationis. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie [in French]. Ann Dermatol Venereol. 2011;138(3):264\u20136. https:\/\/doi.org\/10.1016\/j.annder.2011.01.015.","journal-title":"Ann Dermatol Venereol."},{"issue":"12","key":"513_CR16","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/exd.13408","volume":"26","author":"ME Kubin","year":"2017","unstructured":"Kubin ME, Hellberg L, Palatsi R. Glucocorticoids: the mode of action in bullous pemphigoid. Exp Dermatol. 2017;26(12):1253\u201360. https:\/\/doi.org\/10.1111\/exd.13408.","journal-title":"Exp Dermatol"},{"issue":"12","key":"513_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1111\/exd.13444","volume":"26","author":"A Brulefert","year":"2017","unstructured":"Brulefert A, Le Jan S, Plee J, Durlach A, Bernard P, Antonicelli F, et al. Variation of the epidermal expression of glucocorticoid receptor-beta as potential predictive marker of bullous pemphigoid outcome. Exp Dermatol. 2017;26(12):1261\u20136. https:\/\/doi.org\/10.1111\/exd.13444.","journal-title":"Exp Dermatol"},{"issue":"3","key":"513_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","volume":"138","author":"LS Chan","year":"2002","unstructured":"Chan LS, Ahmed AR, Anhalt GJ, Bernauer W, Cooper KD, Elder MJ, et al. The First International Consensus on Mucous Membrane Pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370\u20139. https:\/\/doi.org\/10.1001\/archderm.138.3.370.","journal-title":"Arch Dermatol"},{"issue":"3","key":"513_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annder.2011.01.014","volume":"138","author":"C Bedane","year":"2011","unstructured":"Bedane C, Prost C, Ingen-Housz-Oro S, Joly P, Bernard P, Centres de reference des maladies bulleuses auto-immunes, Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie. Mucous membrane pemphigoid Guidelines for the diagnosis and treatment Centres de reference des maladies bulleuses auto-immunes Societe Francaise de Dermatologie [in French]. Ann Dermatol Venereol. 2011;138(3):259\u201363. https:\/\/doi.org\/10.1016\/j.annder.2011.01.014.","journal-title":"Ann Dermatol Venereol."},{"issue":"10","key":"513_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archderm.142.10.1268","volume":"142","author":"MP Heffernan","year":"2006","unstructured":"Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol. 2006;142(10):1268\u201370. https:\/\/doi.org\/10.1001\/archderm.142.10.1268.","journal-title":"Arch Dermatol"},{"issue":"3","key":"513_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.annder.2011.01.013","volume":"138","author":"C Prost-Squarcioni","year":"2011","unstructured":"Prost-Squarcioni C, Ingen-Housz-Oro S, Joly P, Bernard P, Bedane C, Centres de reference des maladies bulleuses auto-immunes, Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie. Epidermolysis bullosa acquisita. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie [in French]. Ann Dermatol Venereol. 2011;138(3):274\u20139. https:\/\/doi.org\/10.1016\/j.annder.2011.01.013.","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"513_CR22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/bjd.12041","volume":"168","author":"EM Munyangango","year":"2013","unstructured":"Munyangango EM, Le Roux-Villet C, Doan S, Pascal F, Soued I, Alexandre M, et al. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol. 2013;168(2):381\u201390. https:\/\/doi.org\/10.1111\/bjd.12041.","journal-title":"Br J Dermatol"},{"issue":"12","key":"513_CR23","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F Hubner","year":"2016","unstructured":"Hubner F, Recke A, Zillikens D, Linder R, Schmidt E. Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J Investig Dermatol. 2016;136(12):2495\u20138. https:\/\/doi.org\/10.1016\/j.jid.2016.07.013.","journal-title":"J Investig Dermatol."},{"key":"513_CR24","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJ, West J. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180. https:\/\/doi.org\/10.1136\/bmj.a180.","journal-title":"BMJ"},{"issue":"8","key":"513_CR25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","volume":"132","author":"P Joly","year":"2012","unstructured":"Joly P, Baricault S, Sparsa A, Bernard P, Bedane C, Duvert-Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Investig Dermatol. 2012;132(8):1998\u20132004. https:\/\/doi.org\/10.1038\/jid.2012.35.","journal-title":"J Investig Dermatol."},{"key":"513_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3389\/fmed.2018.00220","volume":"5","author":"K Kridin","year":"2018","unstructured":"Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018;5:220. https:\/\/doi.org\/10.3389\/fmed.2018.00220.","journal-title":"Front Med (Lausanne)."},{"key":"513_CR27","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","volume":"10","author":"K Izumi","year":"2019","unstructured":"Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid. Front Immunol. 2019;10:978. https:\/\/doi.org\/10.3389\/fimmu.2019.00978.","journal-title":"Front Immunol."},{"issue":"1","key":"513_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/ijd.13813","volume":"57","author":"K Kridin","year":"2018","unstructured":"Kridin K, Bergman R. Ethnic variations in the epidemiology of bullous pemphigoid in Israel. Int J Dermatol. 2018;57(1):34\u20139. https:\/\/doi.org\/10.1111\/ijd.13813.","journal-title":"Int J Dermatol"},{"issue":"1","key":"513_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/j.1365-4362.1992.tb03519.x","volume":"31","author":"BA Adam","year":"1992","unstructured":"Adam BA. Bullous diseases in Malaysia: epidemiology and natural history. Int J Dermatol. 1992;31(1):42\u20135. https:\/\/doi.org\/10.1111\/j.1365-4362.1992.tb03519.x.","journal-title":"Int J Dermatol"},{"issue":"4","key":"513_CR30","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1046\/j.1365-2230.2002.01037.x","volume":"27","author":"XH Gao","year":"2002","unstructured":"Gao XH, Winsey S, Li G, Barnardo M, Zhu XJ, Chen HD, et al. HLA-DR and DQ polymorphisms in bullous pemphigoid from northern China. Clin Exp Dermatol. 2002;27(4):319\u201321. https:\/\/doi.org\/10.1046\/j.1365-2230.2002.01037.x.","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"513_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1046\/j.1365-2133.2002.04919.x","volume":"147","author":"SN Wong","year":"2002","unstructured":"Wong SN, Chua SH. Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review. Br J Dermatol. 2002;147(3):476\u201380. https:\/\/doi.org\/10.1046\/j.1365-2133.2002.04919.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"513_CR32","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12026-017-8975-2","volume":"66","author":"K Kridin","year":"2018","unstructured":"Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018;66(1):6\u201317. https:\/\/doi.org\/10.1007\/s12026-017-8975-2.","journal-title":"Immunol Res"},{"key":"513_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16188","author":"R Kakuta","year":"2020","unstructured":"Kakuta R, Kurihara Y, Yamagami J, Miyamoto J, Funakoshi T, Tanikawa A, et al. Results of the guideline-based treatment for pemphigus: a single-centre experience with 84 cases. J Eur Acad Dermatol Venereol. 2020. https:\/\/doi.org\/10.1111\/jdv.16188.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"513_CR34","unstructured":"University Hospital, Rouen. Efficiency and tolerance of rtiuximab (mabthera) in bulous pemphigoid (rituximab2) [ClinicalTrials.gov identifier NCT00525616]. National Institutes of Health, ClinicalTrials.gov. https:\/\/clinicaltrials.gov. Accessed 5 Mar 2020."},{"issue":"10079","key":"513_CR35","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet. 2017;389(10079):1630\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(17)30560-3.","journal-title":"Lancet"},{"issue":"2","key":"513_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","volume":"85","author":"M Amagai","year":"2017","unstructured":"Amagai M, Ikeda S, Hashimoto T, Mizuashi M, Fujisawa A, Ihn H, et al. A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid. J Dermatol Sci. 2017;85(2):77\u201384. https:\/\/doi.org\/10.1016\/j.jdermsci.2016.11.003.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"513_CR37","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling M, Franke A, Aberer E, Glaser R, Hertl M, Pfeiffer C, et al. An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol. 2017;177(5):1299\u2013305. https:\/\/doi.org\/10.1111\/bjd.15649.","journal-title":"Br J Dermatol"},{"issue":"12","key":"513_CR38","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/jdv.15816","volume":"33","author":"K Kridin","year":"2019","unstructured":"Kridin K, Kowalski EH, Kneiber D, Laufer-Britva R, Amber KT. From bench to bedside: evolving therapeutic targets in autoimmune blistering disease. J Eur Acad Dermatol Venereol. 2019;33(12):2239\u201352. https:\/\/doi.org\/10.1111\/jdv.15816.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-020-00513-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-020-00513-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T01:06:54Z","timestamp":1615856814000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-020-00513-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,16]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s40257-020-00513-3","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,16]]},"assertion":[{"value":"16 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study has not been funded by any sources.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Payal M. Patel, Virginia A. Jones, Taryn N. Murray, Kyle T. Amber declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Exempt.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board approval status"}}]}}